Ability of 18F-FDG Positron Emission Tomography Radiomics and Machine Learning in Predicting KRAS Mutation Status in Therapy-Naive Lung Adenocarcinoma
暂无分享,去创建一个
Kuangyu Shi | S. Förster | C. Schmidkonz | W. Hohenforst-Schmidt | Z. Sziklavári | C. Steppert | A. Atzinger | A. Hartmann | Ruiyun Zhang | M. Vieth
[1] A. Brooun,et al. The pharmacologic and toxicologic characterization of the potent and selective KRAS G12D inhibitors ERAS-4693 and ERAS-5024. , 2023, Toxicology and Applied Pharmacology.
[2] Chih-Shia Lee,et al. Abstract B022: A non-conserved histidine residue on KRAS drives paralog selectivity of the KRAS G12D inhibitor MRTX1133 , 2023, Molecular Cancer Research.
[3] S. Digumarthy,et al. Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation , 2021, Cancers.
[4] Lei Peng,et al. Pretreatment 18F-FDG PET/CT Imaging Predicts the KRAS/NRAS/BRAF Gene Mutational Status in Colorectal Cancer , 2021, Journal of oncology.
[5] R. Govindan,et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. , 2021, The New England journal of medicine.
[6] Jia Huang,et al. Integration of clinicopathological and mutational data offers insight into lung cancer with tumor spread through air spaces , 2021, Annals of translational medicine.
[7] Dmitry Cherezov,et al. A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC , 2021, Tomography.
[8] H. Groen,et al. Simultaneous Identification of EGFR, KRAS, ERBB2, and TP53 Mutations in Patients with Non-Small Cell Lung Cancer by Machine Learning-Derived Three-Dimensional Radiomics , 2021, Cancers.
[9] Yan Liu,et al. The Prevalence and Concurrent Pathogenic Mutations of KRASG12C in Northeast Chinese Non-small-cell Lung Cancer Patients , 2021, Cancer management and research.
[10] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[11] Li Zhang,et al. Genomic characteristics of driver genes in Chinese patients with non‐small cell lung cancer , 2020, Thoracic cancer.
[12] H. Saka,et al. Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer? A cross-sectional study in Japan , 2020, BMJ Open.
[13] Haiquan Chen,et al. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features. , 2020, The Journal of thoracic and cardiovascular surgery.
[14] X. Che,et al. Assessment of Nine Driver Gene Mutations in Surgically Resected Samples from Patients with Non-Small-Cell Lung Cancer , 2020, Cancer management and research.
[15] S. Hyun,et al. Imaging phenotype using 18F-fluorodeoxyglucose positron emission tomography–based radiomics and genetic alterations of pancreatic ductal adenocarcinoma , 2020, European Journal of Nuclear Medicine and Molecular Imaging.
[16] J. Fernandez-Banet,et al. The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. , 2019, Cancer discovery.
[17] Hassan Maleki,et al. Next Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Approaches , 2019, ArXiv.
[18] Y. Huang,et al. 18F-FDG PET/CT imaging in pulmonary sarcomatoid carcinoma and correlation with clinical and genetic findings , 2019, Annals of Nuclear Medicine.
[19] S. C. Wang,et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] Chuong D. Hoang,et al. A radiogenomic dataset of non-small cell lung cancer , 2018, Scientific Data.
[21] Wei-Chih Shen,et al. Metabolic Imaging Phenotype Using Radiomics of [18F]FDG PET/CT Associated with Genetic Alterations of Colorectal Cancer , 2018, Molecular Imaging and Biology.
[22] S. Novello,et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] R. Mak,et al. Impact of experimental design on PET radiomics in predicting somatic mutation status. , 2017, European journal of radiology.
[24] John Quackenbush,et al. Somatic Mutations Drive Distinct Imaging Phenotypes in Lung Cancer. , 2017, Cancer research.
[25] Chuong D. Hoang,et al. Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative 18F FDG-PET/CT metrics. , 2017, Oncotarget.
[26] Chintan Parmar,et al. Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non–Small Cell Lung Cancer , 2017, The Journal of Nuclear Medicine.
[27] M. Ahn,et al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.
[28] M. Hatt,et al. (18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status. , 2016, The British journal of radiology.
[29] S. Chiang,et al. Correlation Between PET/CT Parameters and KRAS Expression in Colorectal Cancer , 2014, Clinical nuclear medicine.
[30] M. Lozano,et al. Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[31] Yi-long Wu,et al. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] Patrick Granton,et al. Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.
[33] Nitesh V. Chawla,et al. SMOTE: Synthetic Minority Over-sampling Technique , 2002, J. Artif. Intell. Res..
[34] J. Baselga,et al. ZD1839 ('Iressa') as an anticancer agent. , 2000, Drugs.